- Report
- October 2024
- 191 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- October 2024
- 194 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 233 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- February 2018
- 115 Pages
Global
From €4505EUR$4,950USD£3,862GBP
- Report
- February 2024
- 120 Pages
Global
From €4323EUR$4,750USD£3,706GBP
The Rapid Antigen Detection Test market is a subset of the larger Infectious Disease Testing market. It is composed of tests that detect the presence of antigens, which are molecules that are produced by a pathogen and can be used to identify the presence of a particular infectious agent. These tests are typically used to diagnose acute infections, as they provide results in a short period of time. They are also used to monitor the spread of infectious diseases, as they can detect the presence of antigens in a sample quickly and accurately.
Rapid Antigen Detection Tests are used in a variety of settings, including hospitals, clinics, and laboratories. They are also used in public health settings, such as schools and workplaces, to detect the presence of infectious agents.
Some companies in the Rapid Antigen Detection Test market include Abbott, Becton Dickinson, Cepheid, DiaSorin, and Quidel. Show Less Read more